Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FV-100 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 2 | EXPERIMENTAL | FV-100, 400 mg once daily AND valacyclovir placebo, three times a day, for seven days |
| 3 | ACTIVE_COMPARATOR | Valacyclovir, 1 gram, three times a day AND FV-100 placebo, once daily, for seven days |
| 1 | EXPERIMENTAL | FV-100, 200 mg once daily AND valacyclovir placebo, three times a day, for seven days |
| Name | Type | Description |
|---|---|---|
| valacyclovir | DRUG | 1 gram, three times a day for seven days |
| FV-100 | DRUG | 400 mg, once daily, for seven days |
| Valacyclovir placebo | DRUG | three times a day, for seven days |
| FV-100 placebo | DRUG | once daily, for seven days |
Inclusion Criteria: * Men and women ≥ 50 years of age * Patients with a clinical diagnosis of HZ as evidenced by a unilateral dermatomal rash * Patients with zoster-related pain (ZBPI worst pain score \> 0) * Patients able to be enrolled into the study ≤ 72 hours from appearance of rash (i.e., lesi...